Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Net Cash Provided by (Used in) Operating Activities [Abstract]
Unrealized loss on marketable securities	$ 190,525	$ (4,275,647)
Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]
Stock-based compensation expense	242,660	252,847
Capital in lieu of executive compensation	0	127,516
Change in fair value of convertible debt	(5,424,251)	1,769,000
Increase (Decrease) in Operating Capital [Abstract]
Prepaid expenses, deposits and other assets	(1,549,061)	111,496
Accounts payable	382,675	57,347
Deferred grant revenue	547,051	0
Net cash used in operating activities	(4,911,393)	(1,880,229)
Net assets assumed in connection with reverse recapitalization	11,887,757	0
Proceeds from sale of common stock	810,000	0
Payment of reverse recapitalization costs	(1,455,268)	0
Net cash provided by financing activities	11,242,489	0
Net increase (decrease) in cash and cash equivalents	6,331,096	(1,880,229)
Cash and cash equivalents at beginning of period	4,093,579	6,666,338
Cash and cash equivalents at end of period	10,424,675	4,786,109
Noncash Investing and Financing Items [Abstract]
Conversion of preferred stock to common stock	24,287,211
Merger cost in accounts payable and accrued expenses	93,375
Conversion of Debt into Common Stock [Member]
Noncash Investing and Financing Items [Abstract]
Conversion of Convertible Notes	$ 6,989,749	$ 0